- Home
- VSTM vs FHTX Comparison
VSTM vs FHTX Comparison
Compare VSTM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- FHTX
- Stock Information
- Founded
- VSTM 2010
- FHTX 2015
- Country
- VSTM United States
- FHTX United States
- Employees
- VSTM N/A
- FHTX N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- VSTM Health Care
- FHTX Health Care
- Exchange
- VSTM Nasdaq
- FHTX Nasdaq
- Market Cap
- VSTM 345.6M
- FHTX 278.1M
- IPO Year
- VSTM 2012
- FHTX 2020
- Fundamental
- Price
- VSTM $8.23
- FHTX $4.98
- Analyst Decision
- VSTM Strong Buy
- FHTX Strong Buy
- Analyst Count
- VSTM 9
- FHTX 8
- Target Price
- VSTM $12.75
- FHTX $12.63
- AVG Volume (30 Days)
- VSTM 3.1M
- FHTX 110.7K
- Earning Date
- VSTM 08-07-2025
- FHTX 08-05-2025
- Dividend Yield
- VSTM N/A
- FHTX N/A
- EPS Growth
- VSTM N/A
- FHTX N/A
- EPS
- VSTM N/A
- FHTX N/A
- Revenue
- VSTM $2,137,000.00
- FHTX $24,173,000.00
- Revenue This Year
- VSTM $55.63
- FHTX $33.60
- Revenue Next Year
- VSTM $453.72
- FHTX $5.87
- P/E Ratio
- VSTM N/A
- FHTX N/A
- Revenue Growth
- VSTM N/A
- FHTX N/A
- 52 Week Low
- VSTM $2.24
- FHTX $2.95
- 52 Week High
- VSTM $9.10
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- VSTM 73.06
- FHTX 44.97
- Support Level
- VSTM $7.44
- FHTX $4.48
- Resistance Level
- VSTM $8.76
- FHTX $5.23
- Average True Range (ATR)
- VSTM 0.64
- FHTX 0.39
- MACD
- VSTM 0.23
- FHTX -0.07
- Stochastic Oscillator
- VSTM 84.05
- FHTX 23.65
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.